Clinical Trial

Inflammation Indıces and Mortality in Adult Crush Syndrome

Completed
View on ClinicalTrials.gov →
Summary
This retrospective observational cohort study aims to evaluate the prognostic value of inflammatory hematological indices, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), systemic immune-inflammation index (SII), systemic inflammatory response index (SIRI), and pan-immune-inflammation value (PIV), in predicting 28-day mortality in adult patients with crush syndrome admitted to the intensive care unit (ICU). Patients aged 18 years and older diagnosed with crush syndrome between January 1, 2018, and September 30, 2025, were included. The primary outcome is 28-day mortality. Secondary outcomes include ICU mortality and in-hospital mortality. The predictive performance of inflammatory indices will be compared with established severity scores such as APACHE II and SOFA.
Trial Details
NCT Number NCT07433127
Lead Sponsor Ataturk University
Conditions Crush Syndrome, Rhabdomyolysis, Systemic Inflammatory Response, Critical Illness
Enrollment 325 participants
Start Date 2018-01-01
Primary Completion 2025-10-28 (estimated)
Study Completion 2025-10-28 (estimated)
Updated on ClinicalTrials.gov 2026-02-25